May 24, 2017 - AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.
Apr 19, 2017 - The past year hasn't been kind to shareholders of Alexion Pharmaceuticals, Opko Health, and Novo Nordisk. Do their stocks hold value today, or should they be avoided?
Apr 18, 2017 - Want high dividend yields? Check out healthcare stocks AbbVie, Pfizer, and Novo Nordisk.
Apr 10, 2017 - Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.
Mar 28, 2017 - Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include data from the SWITCH studies.
Mar 28, 2017 - Orexigen Therapeutics, Inc.'s (OREX) announced that it has entered into a commercialization and distributorship agreement with Italian pharmaceutical company, Bruno Farmaceutici, for its obesity drug, Contrave.
Mar 13, 2017 - We issued an updated research report on Novo Nordisk (NVO) on Mar 9, 2017.
Mar 08, 2017 - Merck & Co., Inc. (MRK) and partner Pfizer, Inc. (PFE) announced that the FDA has accepted its new drug applications (NDA) for ertugliflozin as a monotherapy as well as two fixed-dose combination tablets.
Mar 02, 2017 - Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International
Mar 01, 2017 - Pricing to Remain Pharma Headline Risk in 2017